We also demonstrated that both ESRRG and its specific agonist, DY131, suppressed ESCC cell growth by inhibiting the Warburg effect and enhanced the efficacy of immune checkpoint inhibitors. The gene discussed is ESRRG; the disease is esophageal squamous cell carcinoma.